Logo image of ARDX

ARDELYX INC (ARDX) Stock Fundamental Analysis

NASDAQ:ARDX - Nasdaq - US0396971071 - Common Stock - Currency: USD

3.8418  +0.14 (+3.83%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ARDX. ARDX was compared to 559 industry peers in the Biotechnology industry. Both the profitability and financial health of ARDX have multiple concerns. ARDX is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ARDX has reported negative net income.
ARDX had a negative operating cash flow in the past year.
ARDX had negative earnings in each of the past 5 years.
ARDX had a negative operating cash flow in each of the past 5 years.
ARDX Yearly Net Income VS EBIT VS OCF VS FCFARDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -13.11%, ARDX belongs to the top of the industry, outperforming 82.47% of the companies in the same industry.
The Return On Equity of ARDX (-36.91%) is better than 73.35% of its industry peers.
Industry RankSector Rank
ROA -13.11%
ROE -36.91%
ROIC N/A
ROA(3y)-22.18%
ROA(5y)-43.77%
ROE(3y)-43.52%
ROE(5y)-79.37%
ROIC(3y)N/A
ROIC(5y)N/A
ARDX Yearly ROA, ROE, ROICARDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 84.59%, ARDX belongs to the top of the industry, outperforming 88.01% of the companies in the same industry.
In the last couple of years the Gross Margin of ARDX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ARDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
ARDX Yearly Profit, Operating, Gross MarginsARDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

ARDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARDX has more shares outstanding than it did 1 year ago.
ARDX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ARDX has a worse debt to assets ratio.
ARDX Yearly Shares OutstandingARDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ARDX Yearly Total Debt VS Total AssetsARDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 0.10, we must say that ARDX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.10, ARDX is in the better half of the industry, outperforming 63.15% of the companies in the same industry.
A Debt/Equity ratio of 1.04 is on the high side and indicates that ARDX has dependencies on debt financing.
ARDX's Debt to Equity ratio of 1.04 is on the low side compared to the rest of the industry. ARDX is outperformed by 77.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.04
Debt/FCF N/A
Altman-Z 0.1
ROIC/WACCN/A
WACC9.97%
ARDX Yearly LT Debt VS Equity VS FCFARDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 4.12 indicates that ARDX has no problem at all paying its short term obligations.
ARDX has a Current ratio (4.12) which is comparable to the rest of the industry.
ARDX has a Quick Ratio of 3.81. This indicates that ARDX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.81, ARDX perfoms like the industry average, outperforming 45.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.12
Quick Ratio 3.81
ARDX Yearly Current Assets VS Current LiabilitesARDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

ARDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.36%, which is quite impressive.
The Revenue has grown by 127.34% in the past year. This is a very strong growth!
ARDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 129.15% yearly.
EPS 1Y (TTM)20.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.55%
Revenue 1Y (TTM)127.34%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%61.04%

3.2 Future

Based on estimates for the next years, ARDX will show a very strong growth in Earnings Per Share. The EPS will grow by 66.82% on average per year.
Based on estimates for the next years, ARDX will show a very strong growth in Revenue. The Revenue will grow by 22.60% on average per year.
EPS Next Y-138.35%
EPS Next 2Y65.39%
EPS Next 3Y81.63%
EPS Next 5Y66.82%
Revenue Next Year11.49%
Revenue Next 2Y22.53%
Revenue Next 3Y24.95%
Revenue Next 5Y22.6%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ARDX Yearly Revenue VS EstimatesARDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
ARDX Yearly EPS VS EstimatesARDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARDX. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 32.06 indicates a quite expensive valuation of ARDX.
Based on the Price/Forward Earnings ratio, ARDX is valued cheaper than 90.52% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.40. ARDX is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 32.06
ARDX Price Earnings VS Forward Price EarningsARDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARDX Per share dataARDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

ARDX's earnings are expected to grow with 81.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.39%
EPS Next 3Y81.63%

More info and screens

0

5. Dividend

5.1 Amount

ARDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARDELYX INC

NASDAQ:ARDX (6/12/2025, 11:05:09 AM)

3.8418

+0.14 (+3.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners64.68%
Inst Owner Change8.17%
Ins Owners1.84%
Ins Owner Change10.52%
Market Cap919.19M
Analysts85.56
Price Target10.52 (173.83%)
Short Float %11.89%
Short Ratio4.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)138.42%
Min EPS beat(2)-46.66%
Max EPS beat(2)323.5%
EPS beat(4)3
Avg EPS beat(4)101.46%
Min EPS beat(4)-46.66%
Max EPS beat(4)323.5%
EPS beat(8)6
Avg EPS beat(8)70.96%
EPS beat(12)9
Avg EPS beat(12)545.42%
EPS beat(16)10
Avg EPS beat(16)407.06%
Revenue beat(2)1
Avg Revenue beat(2)-2.12%
Min Revenue beat(2)-7.8%
Max Revenue beat(2)3.56%
Revenue beat(4)3
Avg Revenue beat(4)9.35%
Min Revenue beat(4)-7.8%
Max Revenue beat(4)30.48%
Revenue beat(8)6
Avg Revenue beat(8)31.01%
Revenue beat(12)10
Avg Revenue beat(12)33.16%
Revenue beat(16)12
Avg Revenue beat(16)28.18%
PT rev (1m)0%
PT rev (3m)2.54%
EPS NQ rev (1m)-2.71%
EPS NQ rev (3m)-58.36%
EPS NY rev (1m)-57.54%
EPS NY rev (3m)-172.71%
Revenue NQ rev (1m)-1.79%
Revenue NQ rev (3m)-5.87%
Revenue NY rev (1m)-0.84%
Revenue NY rev (3m)-1.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 32.06
P/S 2.54
P/FCF N/A
P/OCF N/A
P/B 6.31
P/tB 6.31
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)0.12
Fwd EY3.12%
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS1.51
BVpS0.61
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.11%
ROE -36.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.59%
FCFM N/A
ROA(3y)-22.18%
ROA(5y)-43.77%
ROE(3y)-43.52%
ROE(5y)-79.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
F-Score3
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 1.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 53.18%
Cap/Sales 0.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.12
Quick Ratio 3.81
Altman-Z 0.1
F-Score3
WACC9.97%
ROIC/WACCN/A
Cap/Depr(3y)26.96%
Cap/Depr(5y)45.67%
Cap/Sales(3y)0.23%
Cap/Sales(5y)4.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.55%
EPS Next Y-138.35%
EPS Next 2Y65.39%
EPS Next 3Y81.63%
EPS Next 5Y66.82%
Revenue 1Y (TTM)127.34%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%61.04%
Revenue Next Year11.49%
Revenue Next 2Y22.53%
Revenue Next 3Y24.95%
Revenue Next 5Y22.6%
EBIT growth 1Y35.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-80.56%
EBIT Next 3Y96.81%
EBIT Next 5Y63.67%
FCF growth 1Y44.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.49%
OCF growth 3YN/A
OCF growth 5YN/A